mTOR (inhibitor)

Class

mTOR inhibitor (repurposed, inhaled)

mTOR (mechanistic target of rapamycin) is an intracellular enzyme, a serine/threonine kinase, that sits at the center of a major growth-control pathway often called PI3K–AKT–mTOR. It exists in two distinct multiprotein complexes, mTORC1 and mTORC2, which integrate signals about nutrient availability, energy status, and growth factor signaling to determine whether a cell should synthesize proteins, grow, divide, or instead conserve resources through autophagy (a recycling process that breaks down and reuses cellular components). Because many cancers and certain non-malignant proliferative diseases depend on excessive mTOR pathway activity, inhibiting this kinase can slow abnormal cell growth. One well-studied example outside oncology is a rare lung disease characterized by unchecked proliferation of smooth-muscle-like cells that destroy lung tissue; here, local delivery of an mTOR inhibitor directly to the airway, rather than systemic dosing, aims to concentrate the drug where it is needed while limiting whole-body exposure. Other approaches use small molecules that inhibit mTOR more broadly, engaging both mTORC1 and mTORC2, for conditions where broader pathway suppression is desired. The overall rationale is the same across these different chemical and delivery strategies: dampen an overactive growth-signaling node without shutting down normal cellular maintenance entirely.